AU2002225219A1 - Diagnosis and treatment of multiple sclerosis - Google Patents
Diagnosis and treatment of multiple sclerosisInfo
- Publication number
- AU2002225219A1 AU2002225219A1 AU2002225219A AU2002225219A AU2002225219A1 AU 2002225219 A1 AU2002225219 A1 AU 2002225219A1 AU 2002225219 A AU2002225219 A AU 2002225219A AU 2002225219 A AU2002225219 A AU 2002225219A AU 2002225219 A1 AU2002225219 A1 AU 2002225219A1
- Authority
- AU
- Australia
- Prior art keywords
- diagnosis
- treatment
- multiple sclerosis
- sclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Computational Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26440401P | 2001-01-26 | 2001-01-26 | |
US60/264,404 | 2001-01-26 | ||
US33164701P | 2001-11-20 | 2001-11-20 | |
US60/331,647 | 2001-11-20 | ||
PCT/GB2002/000330 WO2002059604A2 (en) | 2001-01-26 | 2002-01-25 | Diagnosis and treatment of multiple sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002225219A1 true AU2002225219A1 (en) | 2002-08-06 |
Family
ID=26950517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002225219A Abandoned AU2002225219A1 (en) | 2001-01-26 | 2002-01-25 | Diagnosis and treatment of multiple sclerosis |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1354199A2 (en) |
JP (1) | JP2004532386A (en) |
AU (1) | AU2002225219A1 (en) |
WO (1) | WO2002059604A2 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2774959C (en) | 2000-08-04 | 2016-05-31 | Dmi Biosciences, Inc. | Method of using diketopiperazines and composition containing them |
US7015004B2 (en) | 2001-11-23 | 2006-03-21 | Syn X Pharma, Inc. | Inter-alpha trypsin inhibitor biopolymer marker indicative of insulin resistance |
US20030113808A1 (en) * | 2001-12-13 | 2003-06-19 | George Jackowski | Apolipoprotein biopolymer markers predictive of alzheimers disease |
AU2004222345A1 (en) * | 2003-03-14 | 2004-09-30 | Ppd Biomarker Discovery Sciences, Llc | Biological markers for diagnosing rheumatoid arthritis |
EP2517718B1 (en) | 2003-05-15 | 2016-03-02 | Ampio Pharmaceuticals, Inc. | Treatment of T-cell mediated diseases |
US9408891B2 (en) | 2003-11-12 | 2016-08-09 | The Trustees Of The University Of Pennsylvania | Methods of using gelsolin to treat or prevent bacterial sepsis |
ES2730728T3 (en) | 2004-05-12 | 2019-11-12 | Brigham & Womens Hospital Inc | Use of gelsolin to treat infections |
US20050266467A1 (en) * | 2004-05-19 | 2005-12-01 | Ppd Biomarker Discovery Sciences, Llc | Biomarkers for multiple sclerosis and methods of use thereof |
WO2006005583A2 (en) * | 2004-07-12 | 2006-01-19 | Geneprot Inc. | Secreted polypeptide species involved in multiple sclerosis |
WO2006069739A2 (en) * | 2004-12-27 | 2006-07-06 | Geneprot Inc. | Polypeptide species useful for the treatment of neurological disorders |
WO2006074787A2 (en) * | 2004-12-27 | 2006-07-20 | Geneprot Inc. | Polypeptide species useful for the treatment of neurological disorders |
US20070017809A1 (en) * | 2005-07-21 | 2007-01-25 | Power3 Medical Products, Inc. | Assay for ALS and ALS-like disorders |
AU2007227613A1 (en) * | 2006-03-15 | 2007-09-27 | The Brigham And Women's Hospital, Inc. | Use of gelsolin to diagnose and treat inflammatory diseases |
EP2002258B1 (en) * | 2006-03-15 | 2017-09-27 | The Brigham and Women's Hospital, Inc. | Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases |
JPWO2009020058A1 (en) * | 2007-08-03 | 2010-11-04 | 学校法人慶應義塾 | Drug delivery system for demyelinating lesions and biochemical markers of demyelinating lesions |
EP2522753B1 (en) * | 2007-08-13 | 2014-04-02 | Baxter International Inc. | IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease |
AU2013276992C1 (en) * | 2007-08-13 | 2016-08-11 | Takeda Pharmaceutical Company Limited | IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease |
CA2749985C (en) | 2008-01-25 | 2020-07-07 | The General Hospital Corporation | Therapeutic use of gelsolin in chronic renal failure |
JP5856843B2 (en) | 2008-05-27 | 2016-02-10 | アンピオ ファーマシューティカルズ,インコーポレイテッド | Pharmaceutical composition using diketopiperazine |
WO2010005387A1 (en) * | 2008-07-10 | 2010-01-14 | Astrazeneca Ab | New method and biomarkers for the diagnosis of multiple sclerosis |
US8507496B2 (en) | 2010-09-07 | 2013-08-13 | Dmi Acquisition Corp. | Treatment of diseases |
EP3101426B1 (en) | 2010-12-16 | 2019-05-15 | National Institute of Advanced Industrial Science And Technology | Alpha2-macroglobulin from cerebrospinal fluid as an index marker for neuromyelitis optica |
CN103841987B (en) | 2011-10-10 | 2015-06-17 | 安皮奥制药股份有限公司 | Treatment of degenerative joint disease |
BR112014007657A2 (en) | 2011-10-10 | 2017-04-11 | Ampio Pharmaceuticals Inc | Implantable medical devices with improved immune tolerance and methods for production and implantation |
US10881710B2 (en) | 2011-10-28 | 2021-01-05 | Ampio Pharmaceuticals, Inc. | Treatment of rhinitis |
ITMI20120865A1 (en) * | 2012-05-18 | 2013-11-19 | Antonio Bertolotto | BIOMARCERS FOR PATHOLOGIES OF THE CENTRAL NERVOUS SYSTEM |
SG10201707619RA (en) | 2013-03-15 | 2017-10-30 | Ampio Pharmaceuticals Inc | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
EP3183240A4 (en) | 2014-08-18 | 2018-06-27 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
EP3310375A4 (en) | 2015-06-22 | 2019-02-20 | Ampio Pharmaceuticals, Inc. | Use of low molecular weight fractions of human serum albumin in treating diseases |
RU2694614C1 (en) * | 2019-01-22 | 2019-07-17 | Общество с ограниченной ответственностью "ВЕСТТРЭЙД ЛТД" (ООО "ВЕСТТРЭЙД ЛТД") | Method of pathological process activity determining in patients with multiple sclerosis |
WO2020172262A1 (en) * | 2019-02-19 | 2020-08-27 | James Janine | Chromium composition and methods thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2321160A1 (en) * | 1998-02-13 | 1999-08-19 | Oxford Glycosciences (Uk) Ltd. | Methods and compositions for diagnosis of hepatoma |
-
2002
- 2002-01-25 JP JP2002559670A patent/JP2004532386A/en active Pending
- 2002-01-25 WO PCT/GB2002/000330 patent/WO2002059604A2/en not_active Application Discontinuation
- 2002-01-25 AU AU2002225219A patent/AU2002225219A1/en not_active Abandoned
- 2002-01-25 EP EP02715572A patent/EP1354199A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2004532386A (en) | 2004-10-21 |
EP1354199A2 (en) | 2003-10-22 |
WO2002059604A2 (en) | 2002-08-01 |
WO2002059604A8 (en) | 2002-11-21 |
WO2002059604A3 (en) | 2003-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002225219A1 (en) | Diagnosis and treatment of multiple sclerosis | |
AU2002323258A1 (en) | Diagnosis and treatment of vascular disease | |
AU2002247004A1 (en) | Methods of diagnosis and treatment of osteoporosis | |
AU2003290548A1 (en) | Prevention and treatment of synucleinopathic disease | |
AU2002367535A1 (en) | Diagnosis and treatment of vascular disease | |
AU2002259130A1 (en) | Agents for treatment of hcv and methods of use | |
AU2003268295A1 (en) | "diagnosis and treatment of infertility" | |
AU2002258728A1 (en) | Gene brcc-3 and diagnostic and therapeutic uses thereof | |
AU2002326813A1 (en) | Diagnosis and treatment of vascular disease | |
AU2002305151A1 (en) | Gene scc-112 and diagnostic and therapeutic uses thereof | |
AU2002303261A1 (en) | Gene brcc2 and diagnostic and therapeutic uses thereof | |
AU2002253990A1 (en) | Diagnosis and treatment of inflammation and hyperactive immune conditions | |
AU3760400A (en) | Methods and reagents for the diagnosis and treatment of multiple sclerosis | |
AU2002341880A1 (en) | Diagnosis and treatment of vascular disease | |
AU2002341604A1 (en) | Diagnosis and treatment of vascular disease | |
AU2002330724A1 (en) | Diagnosis, prevention and treatment of cancer | |
AU2003213898A1 (en) | Prevention and treatment of mycoplasma-associated diseases | |
AU2002360696A1 (en) | Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis | |
EP1409734A4 (en) | Diagnosis and treatment of cancer | |
GB2381272B (en) | Diagnosis and treatment of atherosclerosis | |
AU2002210286A1 (en) | Medicine intended for treatment of multiple sclerosis | |
AU2002249891A1 (en) | Compounds and methods for the diagnosis and treatment of babesia infection | |
AU2001267165A1 (en) | Prevention and treatment of mycoplasma-associated diseases | |
AU2002319591A1 (en) | Diagnosis and treatment of vascular disease | |
AU2002330649A1 (en) | Diagnosis and therapy of conditions involving alms1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |